ipilimumab,nivolumab
bms
['start,(-starti),(-starte)', 'nsclc', 'sclc', 'increase,(-increased)']
discussant dr. reminds us of the heterogeneity of stage iii nsclc and our teaching has been to determine resectability before treatment. the increase study starts to challenge that. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him